Fabrazyme Patients Ask FDA To Retool Genzyme's Product Distribution Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
If the agency stops Genzyme from exporting its Fabry disease treatment Fabrazyme (agalsidase beta), there will be enough for U.S. patients, a citizen petition says.
You may also be interested in...
Patent ‘March-In’ Policy Shift Will Likely Drive Uncertainty More Than Price Drops
Biden administration’s new framework will consider whether a product’s price is reasonable in deciding whether to exercise march-in rights. Numerous other factors could limit provision’s impact, but industry is concerned it will discourage firms from licensing government-funded inventions.
Patent ‘March-In’ Policy Shift Will Likely Drive Uncertainty More Than Price Drops
Biden administration’s new framework will consider whether a product’s price is reasonable in deciding whether to exercise march-in rights. Numerous other factors could limit provision’s impact, but industry is concerned it will discourage firms from licensing government-funded inventions.
Drug Shortage Legislation Gains Momentum With Bipartisan House Bill
Momentum is increasing for efforts to require manufacturers to give advance warning of a drug shortage with legislation now filed in both houses of Congress.